Decentralized clinical trials in 2021 — with John Reites
The first technology-enabled remote clinical trial was launched nearly a decade ago, and that field — now generally referred to as “decentralized clinical trials” — has been advancing and gaining traction ever since. But, like so many other remote tools, it’s been greatly accelerated by the COVID-19 pandemic.
On today’s HIMSSCast, host Jonah Comstock and MobiHealthNews Managing Editor Laura Lovett welcome John Reites, CEO and cofounder of THREAD Research, to give us an update on where this new paradigm for clinical trials is today, and where it’s headed.
- The effect of the pandemic on decentralized clinical trials
- Reconciling cultural differences between pharma and tech
- How vaccine trials are their own animal
- How decentralized trials can help improve clinical trial diversity
- The role of consumer wearables in clinical trials today
- Why clinical trial innovation must be global
- How physicians, researchers, and patients are responding to new clinical trial models
- What everyone should know about decentralized clinical trials
More about this episode:
The year for mobile-enabled clinical trials: 2013 or 2030? (Throwback #1)